Profile data is unavailable for this security.
About the company
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
- Revenue in INR (TTM)40.36bn
- Net income in INR7.36bn
- Incorporated1979
- Employees7.71k
- LocationAjanta Pharma LtdAjanta House,, Charkop, Kandivli West,MUMBAI 400067IndiaIND
- Phone+91 2 266061000
- Fax+91 2 266061200
- Websitehttps://www.ajantapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concord Biotech Ltd | 9.71bn | 3.05bn | 171.19bn | -- | 56.90 | -- | 47.73 | 17.64 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
Natco Pharma Ltd. | 38.28bn | 12.78bn | 182.90bn | 3.98k | 14.42 | -- | 12.61 | 4.78 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
Piramal Pharma Ltd | 77.82bn | -333.40m | 187.08bn | 6.30k | -- | -- | 26.90 | 2.40 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
Sanofi India Ltd | 28.51bn | 6.03bn | 187.78bn | 2.17k | 31.15 | 18.50 | 29.23 | 6.59 | 261.78 | 261.78 | 1,237.97 | 440.80 | 1.51 | 2.24 | 21.86 | 13,114,540.00 | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.52 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Pfizer Ltd | 22.19bn | 5.02bn | 189.54bn | 1.70k | 37.75 | -- | 32.85 | 8.54 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 196.07bn | 14.59k | 33.23 | -- | 22.36 | 3.20 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
Piramal Enterprises Ltd | 79.98bn | -20.16bn | 202.96bn | 12.22k | -- | -- | -- | 2.54 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
Laurus Labs Ltd | 49.82bn | 1.88bn | 229.55bn | 5.75k | 122.53 | -- | 40.31 | 4.61 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
Ajanta Pharma Ltd | 40.36bn | 7.36bn | 269.45bn | 7.71k | 36.74 | -- | 30.98 | 6.68 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
Syngene International Ltd | 34.89bn | 5.10bn | 280.16bn | 6.85k | 55.13 | 6.58 | 29.93 | 8.03 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
Gland Pharma Ltd | 49.12bn | 6.59bn | 286.37bn | 4.59k | 43.49 | -- | 30.20 | 5.83 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 289.10bn | 5.10k | 57.08 | -- | 44.93 | 8.54 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 304.85bn | 15.56k | -- | -- | -- | 2.59 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
IPCA Laboratories Ltd | 71.86bn | 5.64bn | 337.03bn | 16.17k | 59.71 | -- | 36.01 | 4.69 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
Biocon Ltd | 146.13bn | 12.00bn | 349.05bn | 3.41k | 29.08 | -- | 11.58 | 2.39 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 349.93bn | 3.68k | 66.14 | -- | 58.55 | 10.57 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
Holder | Shares | % Held |
---|---|---|
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 4.28m | 3.40% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 3.74m | 2.97% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 1.63m | 1.29% |
Kotak Mahindra Asset Management Co. Ltd.as of 31 Mar 2024 | 1.56m | 1.24% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 1.31m | 1.04% |
White Oak Capital Partners Pte Ltd.as of 30 Jun 2023 | 1.18m | 0.94% |
Canara Robeco Asset Management Co. Ltd.as of 31 Mar 2024 | 1.15m | 0.91% |
Tata AIA Life Insurance Co. Ltd.as of 31 Mar 2024 | 1.14m | 0.91% |
Grandeur Peak Global Advisors LLCas of 31 Jan 2024 | 1.07m | 0.85% |
Invesco Asset Management (India) Pvt Ltd.as of 31 Mar 2024 | 1.01m | 0.80% |